PhRMA: Reauthorize Pediatric Drug Laws, Create Guidance

The drug-industry association Pharmaceutical Research and Manufacturers of America (PhRMA) has spoken out in favor of reauthorizing two pieces of legislation designed to encourage research into pediatric therapies, but suggested certain changes to the way pediatric trials are regulated. Speaking at a public meeting hosted by the Institute of Medicine (IOM) April 28, PhRMA representatives urged permanent reauthorization of the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA), saying the legislation helped to remove “significant disincentives for biopharmaceutical companies to conduct clinical trials for pediatric use.”
Clinical Trials Advisor